SCM
PLRX icon

Suvretta Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Suvretta Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-94,700
Closed -$3.07M – 113
2020
Q2 		$3.07M Buy
+94,700
New +$2.51M 0.07% 62

Other funds holding PLRX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Suvretta Capital Management's PLRX Position: Q3 2020 in Review

Suvretta Capital Management sold out of Pliant Therapeutics (PLRX) in Q3 2020, closing a stake of 94,700 shares — an estimated $3.07M sold.

Suvretta Capital Management first reported a position in PLRX in Q2 2020 and held it in 1 quarter. The position peaked at $3.07M in Q2 2020. 55 funds tracked by Wall St. Rank hold PLRX as of Q3 2020.

  • Suvretta Capital Management reported no remaining Pliant Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Suvretta Capital Management sold 94,700 Pliant Therapeutics shares in Q3 2020, an estimated $3.07M.
  • Suvretta Capital Management first reported a position in Pliant Therapeutics in Q2 2020 and held it in 1 quarter.
  • Suvretta Capital Management's Pliant Therapeutics position peaked at $3.07M in Q2 2020.
  • 55 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2020.

Based on Suvretta Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.